Cell Medica, a leader in developing, manufacturing and marketing cellular immunotherapies for the treatment of cancer and infections, has announced key appointments to continue strengthening its senior management team.
- Alain Pralong, PhD, appointed Senior Vice President, Head of Manufacturing Operations
- Stefanos Theoharis, PhD, appointed Senior Vice President and Head of Pipeline Strategy and Corporate Partnering
Alain Pralong will develop and execute the company’s strategy for commercial supply of patient-specific cell products on a global level. Through his previous positions at GSK Vaccines, Crucell, Merck Serono and Roche, Alain has extensive experience in product development and scaling pharmaceutical manufacturing operations. Alain will also oversee Cell Medica’s contract manufacturing relationships.
Stefanos Theoharis will spearhead the company’s pipeline development strategy and strategic partnerships. Stefanos’s understanding of development opportunities in cell and gene therapies will accelerate Cell Medica’s pipeline strategy, which includes sourcing new products through academic and corporate collaborations as well as from in-house R&D.
“The appointments of Alain and Stefanos reflect the substantial progress of our current development programmes and our plans to expand our product pipeline further,” stated Gregg Sando, Chief Executive Officer. “The addition of senior team members with Big Pharma experience, including our earlier appointment of Holger Müller as Head of Commercial Operations, demonstrates the depth of management talent we are building within Cell Medica.”